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Selective serotonin reuptake inhibitors (SSRIs) are the most commonly prescribed
medications for the treatment of mood disorders. Yet, individual response to SSRIs is
highly variable, with only a portion of patients showing the desired therapeutic effect.
To better understand the molecular basis underlying individual variability in response
to SSRIs, here we comparatively studied behavioral and molecular consequences
of chronic treatment with fluoxetine, a widely used SSRI, in two sublines of rats
with constitutionally different serotonin (5HT) homeostasis: the high-5HT and low-5HT
sublines. Platelet 5HT levels, a recognized indicator of SSRI efficacy, were decreased by
fluoxetine treatment in both 5HT-sublines. On the other hand, biologically active plasma
5HT levels were reduced only in high-5HT rats. The anxiolytic effect of fluoxetine was also
evident only in high-5HT rats, as supported by spatio-temporal and ethological behavioral
measures in the elevated plus maze (EPM) test and exploratory behavior measures in
the open field (OF) test. None of the behavioral EPM or OF measures were significantly
altered by fluoxetine treatment in low-5HT rats. Unexpectedly, 5HT levels in cerebral
cortices tended to be reduced only in low-5HT rats. Moreover, the effects of fluoxetine
on cortical expression levels of 5HT-related proteins were also present only in low-5HT
rats, with serotonin transporter (5HTT ) and serotonin receptor type 1a (Htr1a) being
down-regulated, while serotonin receptor type 4 (Htr4) was up-regulated by fluoxetine
treatment. The obtained results support a role of individual 5HT tone as an important
influencing factor on the biological actions of SSRI antidepressants.
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INTRODUCTION
Fluoxetine is one of the most frequently prescribed medications
for the treatment of depression and other behavioral symptoms
associated with a deficiency in serotonin (5-hydroxytryptamine,
5HT) neurotransmission (1). It is the oldest member of the
selective serotonin reuptake inhibitors (SSRIs), drugs that
specifically block activity of the serotonin transporter (5HTT,
SERT), a high-affinity 5HT carrier responsible for reuptake of
5HT from the synaptic cleft. A therapeutic response to SSRIs
occurs only after several weeks of treatment, suggesting that rapid
blockage of 5HT reuptake, followed by an immediate increase in
synaptic 5HT levels, is not sufficient for the therapeutic effect.
Thus, the therapeutic action of chronic SSRI treatment is thought
to result from more complex adaptive changes in the brain
serotonergic system. A primary adaptive mechanism involves
desensitization of the presynaptic 5HT1A autoreceptors, but
roles of other subtypes of 5HT receptors have also been proposed
[for a review see (2)].
Despite the widespread use of SSRIs in the treatment of
depression and other mood disorders, their therapeutic success
shows marked individual variability. An adequate response to
treatment is achieved in only up to 50% of patients with major
depression and some patients experience an initial worsening of
symptoms. In recent decades, much effort has been devoted to
the search for molecular basis and markers of inter-individual
differences in therapeutic response to SSRIs. One of the most
promising lines of research has focused on functional genetic
variants in the human serotonin transporter gene (3). Thus,
a long (L) variant of the upstream regulatory region of the
5HTT gene, conferring higher 5HTT activity compared to the
short (S) variant, has been associated with better response to
SSRI treatment in Caucasian populations (4, 5). Additionally,
lower DNA methylation levels in the 5HTT promoter region,
associated with higher gene expression levels (6), were also found
to predict better response to SSRI treatment (7). The role of
5HTT in modulating behavioral and molecular responses to
SSRIs has also been addressed by experimental studies employing
various animal models, such as rodents with targeted deletion
or overexpression of the 5HTT gene (8, 9) of mouse and rat
strains with innate differences in 5HTT activity (10, 11). These
studies have clearly established 5HTT as a primary target of
SSRIs, but the molecular mechanisms underlying a link between
constitutive 5HTT activity and therapeutic SSRI efficacy are
not well-understood.
By selective breeding of Wistar rats for extreme values of
platelet 5HT level, we have developed an animal model named
the Wistar Zagreb-5HT (WZ-5HT) rat, comprising of two
sublines of animals with inherited differences in blood 5HT levels
(12). Subsequent studies have shown that animals from our high-
5HT and low-5HT sublines also display constitutionally altered
(i.e., up-regulated or down-regulated, respectively) platelet 5HTT
activity (13). Since 5HTT in platelets and neurons is encoded
by the same gene, it was expected that rats from WZ-5HT
sublines would also differ in brain serotonergic homeostasis.
Indeed, neurochemical, behavioral and neuropharmacological
studies provided evidence for differential functionality of central
5HT systems between 5HT-sublines. Thus, animals from the
high-5HT subline, compared to the low-5HT subline, show
higher 5HT turnover and 3H-citalopram binding in several brain
regions as well as higher KCl- and citalopram-induced elevation
in extracellular 5HT in hippocampal tissue (14). A number of
functional traits modulated by central and/or peripheral 5HT
signaling differ between 5HT sublines (15–20) and the pattern
of changes is consistent with relatively higher whole-body 5HT
activity in high-5HT as compared to low-5HT animals.
To better understand the molecular basis underlying inter-
individual variability in response to SSRI pharmacotherapy,
here we comparatively studied behavioral and molecular
consequences of chronic fluoxetine treatment in rats from
high-5HT and low-5HT subline. In previous studies, we have
shown that animals from the respective sublines display different
performance in an open field (OF) and elevated plus maze
(EPM) tests (15, 16), a two well-known paradigms for assessing
functioning of brain regions involved in anxiety (21). Hence,
here we investigated fluoxetine-induced changes in the behavior
of WZ-5HT rats in OF/EPM tests. In addition, we assessed
the expression levels of several key genes regulating 5HT
neurotransmission in the frontal cortex, an important brain
region involved in antidepressant actions, and examined 5HT




Studies were performed on high-5HT and low-5HT sublines of
the WZ-5HT rats, developed at the Ruder Bošković Institute,
Zagreb, Croatia, by selective breeding of Wistar rats toward
extremes of their platelet serotonin levels (PSL) and velocity
of platelet serotonin uptake (PSU). Development of the WZ-
5HT rats has been described elsewhere (12, 13). Briefly, at
the age of 5–6 weeks, PSL and PSU were determined in
all offspring of each breeding generation and the males and
females displaying the extreme values of both parameters were
mated to start a next generation. After 5–6 generations of
selective breeding, the divergence of mean values of platelet
5HT parameters between 5HT sublines stabilizes at about 70%
(low-5HT subline) and 150% (high-5HT subline) of the initial
(unselected) population (12). Selective breeding was restarted ab
ovo for several times during the past decades with essentially
the same final divergence of sublines, confirming reproducibility
of the directed selection process. In the present study 13–14
weeks old male WZ-5HT rats were used. They were housed 3
per cage with free access to commercial rat chow (4RF18 GLP,
Mucedola Srl, Settimo Milanese, Italy) and tap water, and were
kept under controlled conditions (23± 2◦C, 55± 10% humidity,
12 h light/12 h dark). All experiments were approved by the
institutional and national (Ministry of Agriculture, Republic of
Croatia) ethical committees and were conducted in accordance
with the EU directive on the protection of animals used in
scientific purposes (2010/63/EU) and ILAR Guide for the Care
and Use of Laboratory Animals.
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Treatment of Animals and the Timeline of
Analyses
Animals from high-5HT and low-5HT sublines were treated with
intraperitoneal (i.p.) injection of vehicle (0.9% saline; n = 8 per
subline) or fluoxetine hydrochloride (a gift from Lilly Research
Laboratories, Indianapolis, IN, USA; n = 17 per subline) for 27
days. Because of the expected greater interindividual variability
in the behavioral response of drug-treated animals compared
to vehicle-treated animals, a larger number of fluoxetine-treated
animals per subline was included. The daily dose of fluoxetine
(6 mg/kg of body weight) was chosen based on literature data.
In rodents, chronic fluoxetine treatment is usually administered
at a dose of 5–10 mg/kg/day for 2–4 weeks (22–25). We used
a moderate daily dose of 6 mg/kg, which mimics well the
therapeutic doses of the drug in human patients (see Discussion
for more details), and chose a longer treatment period (27 days)
to allow sufficient time interval between blood collection and
behavioral testing. The drug solution in 0.9% saline was freshly
prepared each day and administered at a dosage of 0.5 ml/100 g
of body weight. Blood sampling and behavioral experiments
were started 24 h after a pre-determined number of injections,
while brain samples for neurochemical and molecular analyses
were obtained after 48 h drug wash-out period. The timing for
measuring blood 5HT parameters was based on our previous
results with fluvoxamine (18), which showed that platelet 5HT
levels in the treated group remained stably low from day 4 of
treatment onwards, so a similar time-response could be expected
in the present study with fluoxetine. All drug treatments were
done between 9 and 10 a.m. except on the days of blood sampling
and behavioral testing, when the drug was given immediately
after completion of the respective procedures. The time-line
of biochemical, behavioral and molecular biological analyses is
shown in Figure 1.
Blood Sampling and 5HT-Related
Biochemical Measurements
Protocols for repetitive rat blood sampling, preparation of
platelet-rich plasma (PRP) and determination of PSL and PSU
have been described elsewhere (26, 27). In short, venous blood
was withdrawn by jugular venipuncture and PRP was isolated
by centrifugation (1,050×g for 25 s). PSU was determined
radiometrically by incubating aliquots of PRP with 0.5µM
14C-5HT followed by rapid cooling and vacuum filtration.
At this 5HT concentration the velocity of PSU is ∼70% of
the maximal velocity (Vmax) (13). For measurement of PSL,
platelets were pelleted, homogenized by sonication and 5HT
content was quantified spectrophotofluorimetrically and related
to platelet protein. Platelet-free plasma (PFP) was obtained by
a two-step centrifugation: anticoagulated blood was centrifuged
(1,050×g for 4min), the upper layer of supernatant plasma was
carefully collected, recentrifuged for 30min and collected PFP
was stored at−80◦C for further testing. 5HT levels in plasma and
brain tissue were analyzed by enzyme-linked immunosorbent
assay (ELISA; Demeditec Diagnostics GmbH, Kiel, Germany
and IBL International GmbH, Hamburg, Germany, respectively)
according protocol supplied by the manufacturer.
Behavioral Testing
Behavioral performance of the animals was assessed by the
open field (OF) and elevated-plus maze (EPM) tests. Animals
were naive to the test situations and were brought into the
test room 1 h before testing. The activity of each rat during
tests was recorded by web camera fixed above the behavioral
apparatus and connected to computer outside the test room.
Videos were analyzed using the ANY-maze video tracking system
(Stoelting Co,Wood Dale, IL, USA). Behavioral apparatuses were
thoroughly cleaned with a 70% ethanol after each test session
to remove any odor residue. Rats from high-5HT and low-5HT
sublines were always tested alternately.
Open Field Test
The OF test was performed in a rectangular arena (60 ×
60 × 40 cm) made of white painted wood and virtually
divided into border (12.5 cm from the edge) and central
zone. Animals were placed, facing the wall, in the brightly
illuminated arena (300 lux, light bulb 90 cm above the arena)
and allowed to explore it for 5min. Behavioral parameters
recorded were: number of entries and time spent in central and
border zones (measuring anxiety/exploration), distance traveled
and mean speed (ambulation), frequency and time spent in
rearing (exploration/locomotion), and grooming (displacement
response) activity. Latencies to the first onset of activity (entry
into central zone and rearing and grooming in the border zone)
were also recorded. Rearing was defined as standing on the hind
limbs and grooming included cleaning any part of the body
surface with the tongue, teeth and/or forepaws.
The anxiolytic effect was assessed by both conventional
(increased number of entries and time spent in the central
zone and decreased time spent in the border zone) and non-
conventional (increased frequency and time spent in rearing in
the central zone and increased grooming in the whole apparatus)
behavioral measures.
Elevated Plus Maze Test
The EPM test was performed in an apparatus consisting of two
sets of opposing arms: two open (50 × 10 cm) and two enclosed
(50× 10 cm, surrounded by 40 cmhighwalls) armsmade of black
plexiglas and elevated 1m above the floor. The central platform
at the junction of the four arms was 10× 10 cm. The illumination
(light bulb 90 cm above the maze) was 125 lux in the open arms
and 60 lux in the closed arms. Animals were placed on the central
platform, with a head facing an open arm and allowed to explore
the maze for 5min. The following behavioral parameters were
analyzed: number of entries and time spent in open and enclosed
arms and on the central platform (anxiety/exploration), distance
traveled in the enclosed arms and during the whole test and
average speed during the test (ambulation), frequency and time
devoted to rearing in enclosed arms (exploration/locomotion),
as well as head dip number, duration and latencies to onset in
both, open arms, and on the central platform (exploration/risk
assessment). Entries were counted if minimum of 85% of the
animal area was in the arm zone. Head-dipping was defined as
exploratory leaning to the floor from the open arms and central
square. The collected data were further used to calculate derived
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FIGURE 1 | A scheme illustrating experimental design and time course of analyses. At the age of 5–6 weeks (60 days before the start of the treatment), animals from
high-5HT and low-5HT subline were subjected to blood sampling for verification of platelet serotonin level (PSL) and platelet serotonin uptake (PSU). At the age of
13–14 weeks, rats from both sublines were randomly divided into two groups and for the following 27 days were daily treated with i.p. injections of either vehicle (n =
8 per subline) or fluoxetine (6 mg/kg; n = 17 per subline). On day 10 of treatment, all animals receiving vehicle and subset of animals receiving fluoxetine (n = 8 per
subline) were subjected to blood sampling for PSL and PSU measurements. On days 17 and 23 of treatment, all animals underwent behavioral assessment in open
field (OF) and elevated plus maze (EPM) test, respectively. 48 h after the last (27th) injection of vehicle or fluoxetine, animals were sacrificed, and cortical brain tissue
samples were taken for 5HT level measurements and gene expression analyses.
behavioral measures: % entries open and % time open (based on
total entries and total test duration), the ratio between open time
and closed time and the index of open arm avoidance calculated
as follows: 100–[(% time on open arms + % entries to open
arms)/2] (28).
As in the OF test, anxiolytic effect was assessed by both
conventional (increased number of entries and time in open
arms, increased % of time and % of entries in open arms) and
non-conventional (increased head dip number and time in open
arms) behavioral measures. Increased ratio of time in open to
closed arms and decreased index of open arm avoidance were
also considered anxiolytic markers (28). In both tests, measures
of locomotor activity were not considered indicators of anxiolytic
but of sedative/excitatory effect of fluoxetine.
Brain Tissue Sampling
Brains were removed from the skull, rapidly cooled on dry-
ice powder for 10 s, and then placed with ventral side facing
the cold metal plate for dissection. Manual coronal sections
were made with razor blade and cortex tissues, containing
the pre-frontal cortices, were separated. Tissue samples for
gene expression analyses were rapidly frozen in liquid nitrogen
and, prior to storage at −80◦C, homogenized in a denaturing
solution containing 4M guanidine thiocyanate (Sigma-Aldrich,
Merck KGaA, Darmstadt, Germany). Cortical tissue samples
for 5HT determinations were directly stored at −80◦C until
further processing.
Gene Expression Analyses
Total RNA from ∼60mg of cortical tissue was isolated by
standard acid guanidinium-phenol-chlorophorm extraction and
additionally purified by RNeasy Mini Kit (Qiagen, Germantown,
MD, USA) according to the manufacturer’s protocol with
optional on-column DNA digestion step. Concentration and
purity of isolated RNAs were assessed by spectrophotometry
(NanoDrop, ND-1000, Thermo Fisher Scientific, Waltham,
MA, USA); A260/A280 ratios ranged between 2.04 and 2.09.
Aliquots of RNA were subjected to agarose gel electrophoresis
to check integrity; all samples showed sharp 28S and 18S
bands at ratio of ∼2:1. RNA samples were stored at −80◦C
until further processing. Expression levels of genes encoding
the 5HT transporter (5HTT), 5HT receptor subtypes 1A
(Htr1a), 2A (Htr2a), and 4 (Htr4) were analyzed using the
reverse transcription (RT) - quantitative PCR (qPCR) based
on SyberGreen detection chemistry. First strand cDNA was
synthesized from 2 µg of each RNA in a final volume of 20
µl using the High Capacity RNA to cDNA Synthesis Kit (Life
Technologies, Thermo Fisher Scientific, Waltham, MA, USA)
according to the manufacturer’s protocol. Control reactions
lacking reverse transcriptase (no-RT) were prepared to test
for contamination with genomic DNA. cDNAs were diluted
to concentration of 10 ng/µl and stored in small aliquots
at −20◦C. Sequences of primers used in qPCR are listed
in Supplementary Table 1. qPCR assays were prepared using
the SyberGreen Master Mix and run on a 7300 Real Time
PCR System (both from Applied Biosystems, Thermo Fisher
Scientific, Waltham, MA, USA) according to the manufacturer’s
recommendations. Each qPCR plate included a 5-point standard
curve with 2-fold serial dilution and all reactions were performed
in triplicates. The quantification cycles (Cq) in no-RT controls
were either undefined or more than 15 cycles higher than
that obtained from the respective cDNA samples. Relative
expression levels were determined using a relative standard curve
method, and the mean relative expression level of two reference
genes, glyceraldehyde-3-phosphate dehydrogenase (Gapdh) and
actin beta (Actb), was used for normalization of expression
levels (29).
Statistical Analyses
Data were analyzed using GraphPad Prism, version 6.00
(GraphPad Software, San Diego, CA, USA). Normality of the
data distribution was tested by D’Agostino-Pearson omnibus
test and the presence of outliers by Grubb’s test. Experimental
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FIGURE 2 | Platelet serotonin parameters in high-5HT and low-5HT animals
included in the experiments. (A) Platelet 5HT level and (B) velocity of platelet
5HT uptake, relative to platelet protein levels, were measured as described in
the Methods section. Individual values and bars representing means ± SD of
25 animals per subline are shown. Values of 5HT level were 1.62 ± 0.21 and
0.86 ± 0.13, and of 5HT uptake velocity were 0.82 ± 0.13 and 0.45 ± 0.06,
for high-5HT and low-5HT rats, respectively. p-values obtained with Student
t-test. Values of both parameters in unselected animals are intermediate to
those of the sublines. ****p < 0.0001.
groups were compared by one-way analysis of variance (1w-
ANOVA) when data were normally distributed, or by Kruskal-
Wallis (KW) test if data deviated from normal distribution.
Post-hoc analyses were performed using Fisher’s least significant
difference (LSD) test (following 1w-ANOVA) or Dunn’s test
(following KW test). Results are expressed as means ± standard
deviation (SD) or medians with interquartile range (IQR), as
appropriate. Differences were considered statistically significant




Platelet 5HT parameters of the animals included in the
experiments are shown in Figure 2. Rats from high-5HT
and low-5HT subline displayed ∼2-fold differences in platelet
5HT levels (Figure 2A) and platelet 5HT uptake velocity
(Figure 2B). Fluoxetine treatment for 9 consecutive days induced
a prominent reduction in platelet 5HT levels in both high-5HT
and low-5HT rats (by 74 and 81%, respectively; Figure 3A). In
contrast, plasma 5HT levels (Figure 3B) in rats from the two
sublines were differently affected by drug treatment. Fluoxetine
significantly decreased plasma 5HT levels only in animals
from high-5HT subline (by 29%, p < 0.001) while low-5HT
rats showed merely a tendency toward decreased plasma 5HT
levels (15%, n.s.).
Behavioral Measures
On day 17 of fluoxetine treatment, animals were subjected to
behavioral testing using the open field (OF) paradigm. Figure 4
shows values of the measured behavioral parameters in the
treated animals relative to the vehicle group of the same subline.
The absolute values of all measured parameters and the complete
statistical data are given in Supplementary Table 2. In high-5HT
rats (Figure 4A), fluoxetine increased the number (by 61%, p
= 0.015) and time (by 88%, p < 0.001) of rearing episodes in
border zone of the OF apparatus, time (by 72%, p = 0.022)
of grooming episodes in border zone, as well as motor activity
measured as distance traveled in border zone (by 81%, p =
0.006) and total speed performance (by 76%, p = 0.004). In
contrast, none of the mentioned parameters were significantly
affected by fluoxetine treatment in rats from low-5HT subline
(Figure 4B). The number of entries and time spent in the
central zone were not altered by fluoxetine treatment in either
5HT-subline (Figure 4).
One week later (day 23 of fluoxetine treatment), we repeated
the behavioral testing, this time using the elevated plus maze
(EPM) paradigm. Figure 5 shows values of measured behavioral
parameters in treated animals relative to the respective vehicle
groups. The absolute values of all measured parameters and the
complete statistical data are given in Supplementary Table 3. In
high-5HT rats (Figure 5A), fluoxetine induced either significant
changes or a clear trends in several anxiety-related behavioral
measures. Thus, changes or trends were present in time spent
in open arms (increase of 49%, p = 0.064), percentage of time
spent in open arms (increase of 50%, p = 0.064), percentage
of entries into open arms (increase of 35%, p = 0.035),
ratio of open time to closed time (increase of 68%, p =
0.062), head dip number (increase of 49%, p = 0.024), head
dip time (increase of 61%, p = 0.029), and index of open
arm avoidance (decrease of 20%, p = 0.014), all indicating
anxiolytic-like effect of fluoxetine in this subline. However,
none of the aforementioned conventional or ethological EPM
parameters were altered by fluoxetine treatment in low-5HT
animals (Figure 5B). Parameters measuring horizontal and
vertical locomotor activity in EPM test (distance traveled
and rearing in enclosed arms, speed performance) were
not altered by fluoxetine treatment in either 5HT subline
(Figure 5). One of 17 animals in the fluoxetine-treated
5HT-low group was excluded from the statistical analyses
because of almost complete immobility in both behavioral
tests (outlier).
Molecular Changes in the Frontal Cortex
After the wash-out period, animals were sacrificed, and frontal
cortex samples were collected. In high-5HT rats, cortical 5HT
levels were similar in the vehicle- and fluoxetine-treated groups,
while in low-5HT rats, cortical 5HT levels tended to decrease (by
20%, p = 0.070) in fluoxetine compared to vehicle-treated group
(Figure 6). Levels of serotonin transporter (5HTT) mRNA in the
frontal cortex were also not altered by fluoxetine treatment in
high-5HT subline, but were decreased (by 37%, p = 0.003) in
low-5HT subline (Figure 7A). Moreover, high-5HT rats showed
no significant changes in cortical levels of serotonin receptors
type 1a (Htr1a), 2a (Htr2a), and 4 (Htr4) mRNAs in response
to fluoxetine treatment (Figure 7). By contrast, in low-5HT rats,
fluoxetine down-regulatedHtr1a (by 22%, p= 0.008) and tended
to decreaseHtr2a (by 13%, p= 0.069), but up-regulatedHtr4 (by
38%, p= 0.0002) mRNA levels (Figure 7).
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FIGURE 3 | Effects of fluoxetine on (A) platelet 5HT levels, and (B) platelet-free plasma 5HT levels in animals from high-5HT and low-5HT subline (F3,28 = 373 and
8.23, p < 0.0001 and p = 0.0002, respectively, 1w-ANOVA). Blood was collected from the jugular vein after 9 days of treatment. Data are shown as individual values
with group means and SD, n = 8 per group. p-values obtained by post-hoc (Fisher’s LSD) test are given. H = high-5HT animals, L = low-5HT animals, veh = vehicle,
flx = fluoxetine. *p < 0.05 and ****p < 0.0001.
FIGURE 4 | Effect of 16-day fluoxetine treatment on the behavior of (A) high-5HT and (B) low-5HT animals in the open field test. Measured behavioral categories are
indicated in the X-axis legend. All values are relative to the mean/median values of the respective vehicle group (set to 100%, dotted line). Data are presented as
means and SD or medians and upper quartile (Q3), n = 8 (vehicle-treated) or 16–17 (fluoxetine-treated). p-values obtained by LSD or Dunn’s post-hoc test after
1w-ANOVA or KW test, respectively, are indicated. Full statistical data, together with absolute values of all measured parameters, are given in
Supplementary Table 2. H, high-5HT animals; L, low-5HT animals; veh, vehicle; flx, fluoxetine. *p < 0.05 and **p < 0.01.
DISCUSSION
In the present study we used rat model consisting of two sublines
with constitutionally different 5HT homeostasis to better
understand the role of endogenous 5HT tone in modulating
individual sensitivity to SSRI antidepressants. Fluoxetine was
chosen as the most commonly prescribed SSRI in humans and
was administered at a relatively low daily dose that could well
mimic the therapeutic dose in patients. In rodents, fluoxetine
plasma levels sufficient for therapeutic effect are achieved at a
much lower dose than in humans and even a daily dose of 3
mg/kg increased extracellular 5HT after 2 weeks of treatment
(30). The actions of fluoxetine (and other SSRIs) have been
previously investigated in rodent models with genetically altered
5HT homeostasis but our study is the only one using animals with
constitutionally up- and down-regulated 5HT transporter, whose
activity in both sublines is still within the limits of physiological
levels (18), thus likely modeling functional polymorphisms in the
human 5HTT gene.
The main finding of this study is that animals with
constitutive differences in 5HT activity/homeostasis exhibit
differential behavioral sensitivity to fluoxetine. Specifically, in
behavioral categories measured by OF and EPM tests, chronic
fluoxetine treatment induced significant changes only in animals
from high-5HT subline, but not in the low-5HT subline. The
anxiolytic effect in high-5HT animals was evident in the increase
(significant or trend) in traditional spatio-temporal measures
in the EPM test while, surprisingly, in low-5HT animals there
were opposite trends. In the OF test fluoxetine treatment did not
affect anxiety-like behavior in either subline. This inconsistency
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FIGURE 5 | Effect of 22-day fluoxetine treatment on the behavior of (A) high-5HT and (B) low-5HT animals in the elevated plus maze test. For detailed explanation
see legend to Figure 4. Complete statistical data and absolute values of all measured parameters are provided in Supplementary Table 3. *p < 0.05.
FIGURE 6 | 5HT content in the frontal cortex tissue. Cortical tissue was
collected 48 h after the 27th injection of vehicle or fluoxetine. Data from
individual animals are shown and group means ± SD are indicated, n = 8 per
group [F3, 28 = 3.173, p = 0.0396, 1w-ANOVA; p-value obtained by Fisher’s
LSD post-hoc test is given]. H, high-5HT animals; L, low-5HT animals; veh,
vehicle; flx, fluoxetine.
between the OF and EPM results might be due to differences
in treatment duration prior to the behavioral testing (16 and 22
days, respectively), and/or to different settings of the respective
tests, i.e., mild stress of open arena vs. higher stress triggered by
EPM (31). It should be noted that the absence of a fluoxetine
effect on anxietymeasures in theOF test is consistent with reports
that this test is not sensitive to the anxiolytic-like effect of SSRIs,
but only to the effect of benzodiazepines and 5HT1A receptor
agonists (32).
Regarding exploratory behavior, rearing number and time
measured in the OF test were also increased only in high-5HT
animals. This effect was not due to a change in mobility (number
of entries into enclosed arms and distance traveled in EPM test
were not affected) and is, therefore, consistent with the anxiolytic
effect of fluoxetine in this subline.
Assessment of ethologically relevant measures of anxiety
further supported differences in behavioral responsiveness to
fluoxetine between sublines. Thus, the increased number and
time of head dips in fluoxetine-treated high-5HT rats in EPM
test indicated their increased tendency to actively explore the
potentially dangerous area. Since head dipping is negatively
correlated with anxiety (33), these data strengthen the conclusion
about the anxiolytic effect of fluoxetine in high-5HT animals. It
has been suggested that ethological measures are more sensitive
to anxiety-modulating drugs than traditional ones (34), but in
our model they showed a compliant response.
A behavioral issue that needs to be addressed is the
observation that fluoxetine-induced changes in grooming
behavior, similar to the behavioral categories discussed above,
were present only in high-5HT animals. However, the observed
increase in grooming expression is difficult to interpret in terms
of anxiety. Grooming in OF/EPM tests has either been classified
as a displaced behavior (35) and considered an anxiogenic
response [ref. in (36)] or has been shown to represent an isolated
behavioral dimension not associated with anxiety (33, 37). As
for fluoxetine, its chronic administration either did not change
(34) or increased self-grooming (38). It has been suggested that
pharmacologically-induced grooming in rodents may be a model
for obsessive-compulsive disorder (OCD) in humans (39). Since
OCD has been associated with altered brain 5HT availability, and
SSRIs are themainstay of its treatment (40) our high-5HT subline
may deserve further investigations in this regard.
Preclinical studies on the effect of chronic SSRIs treatment
on anxiety behavior are rather contradictory, showing anxiolytic-
like (about 40% studies), anxiogenic-like (20% studies) or
negative outcomes [reviewed by (41)]. Our results show that
individual endogenous 5HT tone may modulate direction
of behavioral response to fluoxetine, and associate higher
constitutional 5HT activity with the anxiolytic effect of
fluoxetine. Because fluoxetine and other SSRIs are widely used
to treat both depression and anxiety, future research examining
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FIGURE 7 | Effects of fluoxetine on cortical expression levels of serotonin-regulating genes. (A) Serotonin transporter [F3, 26 = 3.747, p = 0.0232, 1w-ANOVA], (B)
5HT receptor subtype 1a (KW = 7.93, p = 0.0475, Kruskal-Wallis test), (C) 5HT receptor subtype 2a [F3, 28 = 2.003, n.s., p = 0.136, 1w-ANOVA] and (D) 5HT
receptor subtype 4 [F3, 28 = 9.59, p = 0.0002, 1w-ANOVA]. Cortical tissue was harvested 48 h after the 27th injection of vehicle or fluoxetine. Expression levels are
normalized to the mean of two reference genes, glyceraldehyde-3-phosphate dehydrogenase and actin beta. Data from individual animals are shown and group
means ± SD (A,C,D) or group medians and IQR (B) are indicated (n = 7–8 per group). p-values obtained with Fisher’s LSD (following 1w-ANOVA) or Dunn’s test
(following KW) are given. H, high-5HT animals; L, low-5HT animals; veh, vehicle; flx, fluoxetine. **p < 0.01 and ***p < 0.001.
the effect of SSRI treatment on depression-like behaviors
in 5HT sublines is warranted. Our present results add to
findings that natural variation between rodent strains in 5HT
transporter binding/function is, at least in part, responsible
for individual differences in SSRI sensitivity (10, 11, 42). Our
results strengthen these findings as our rat sublines share
the same strain background. These findings also parallel the
observation that heterozygous 5HTT mutant mice, which exhibit
increased serotonergic transmission, were more sensitive to the
SSRI antidepressant fluvoxamine compared to wild-type mice
(43). They are also consistent with the findings in humans
showing that individuals carrying the high-expressing L allele
of the 5HTT promoter polymorphism respond better to SSRIs
treatment (4, 5).
Serotonin is involved in almost all physiological functions,
so the differences in behavioral responsiveness to fluoxetine
between our sublines could be related to various physiological
processes. First, animals from 5HT sublines might have different
susceptibility to stress they faced in the test apparatus – the
fluoxetine-induced impairment of stress coping ability (44) may
be modulated by the different stress-coping style of the 5HT
sublines (shown at the first exposure to forced swimming test,
personal observation). The next factor could be the difference
in baseline performance in OF/EPM tests - 5HT sublines show
small but consistent differences in anxiety-like behavior, i.e.,
higher anxiety is present in high-5HT rats (15, 16). The finding
that more anxious high-5HT animals are more sensitive to
chronic fluoxetine treatment is consistent with reports that
antidepressants can have a profound effect in anxious patients
but not in healthy individuals (45, 46), as well as with the
finding that of the four mouse strains tested, only the most
anxious one exhibited sensitivity to fluoxetine (47). Further,
the differential sensitivity of our sublines to fluoxetine could
be due to the developmental exposure to different levels of
5HT. It has been shown that pharmacologically increased
5HT activity during the prenatal/neonatal period leads to
altered responsivity to SSRI treatment in adulthood (48). In
5HT sublines, the up- or down-regulation of 5HT activity
is constitutional, i.e., present also during ontogeny. In this
regard, the absence of behavioral effects of fluoxetine treatment
in low-5HT rats is consistent with findings that congenital
brain 5HT deficiency, caused by genetic manipulation of brain
5HT synthesis, reduces the efficacy of fluoxetine (49). Of note,
the increase in extraneuronal 5HT concentration provoked by
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citalopram infusion is less pronounced in low-5HT than high-
5HT rats (14).
SSRIs modulate serotonergic transmission by inhibiting the
reuptake of 5HT from the extracellular space but how they
achieve their antidepressant effect is still unclear. The same
mechanism of SSRI action is responsible for their effect on
peripheral cells, among which blood platelets are the most
investigated. The true relationship between platelet/plasma and
synaptic/extrasynaptic 5HT levels is uncertain, but blood 5HT
parameters have long been studied as potential biomarkers of
disease state or treatment response and prediction.
In our hands fluoxetine administration for 10 days
significantly reduced platelet 5HT levels, as also shown in
numerous experimental and clinical studies, and the extent of the
reduction was similar in both sublines. In contrast, a significant
reduction in platelet-free plasma 5HT levels was observed only in
high-5HT rats. Long-term pharmacological blockade of platelet
5HT uptake is expected to increase 5HT concentrations in the
extracellular compartment, so this decrease in plasma 5HT levels
should be due to adaptive changes other than inhibition of 5HT
uptake alone. Our results suggest that these adaptations may
differ between 5HT sublines. Considering that plasma 5HT levels
were downregulated by fluoxetine treatment only in the subline
that showed anxiolytic effect of fluoxetine (5HT-high subline), it
could be speculated that this parameter may be a potential early
biomarker of behavioral response. A decrease of plasma 5HT
levels by SSRI treatment has been found in several clinical studies
(50–52), although there are also studies showing the opposite.
Under basal conditions, high-5HT as compared to low-5HT
animals have increased 5HT levels not only in platelets but also
in platelet-free plasma [(18); Figure 2B], so their better response
to fluoxetine is in line with the recent clinical study reporting
that individuals with higher pretreatment plasma 5HT levels are
better responders to SSRI drugs (52).
To better understand the neurobiological mechanisms
underlying the differences in functional response of 5HT
sublines to fluoxetine, we analyzed also 5HT levels and
expression of selected 5HT-related genes in the brain frontal
cortical area, which play an important role in depression and
anxiety (53). Surprisingly, at the given post-treatment time-
point, neurochemical and molecular changes were present
only in the brains of low-5HT rats, i.e., animals that did not
show behavioral response to fluoxetine. Thus, cortical 5HT
concentrations tended to be decreased in fluoxetine-treated
low-5HT rats while they were unchanged in high-5HT rats.
Reduction of tissue 5HT level in terminal brain regions by SSRI
treatment has been frequently reported (54–57), and has been
shown to depend on the dose and duration of treatment (58) as
well as on genetic background (55, 59).
With regard to gene expression, we focused on genes encoding
5HTT, as a direct target of fluoxetine, and 5HT receptors Htr1a,
Htr2a, and Htr4, as they have been implicated in therapeutic
response to antidepressant drugs (60–62). Cortical expression
levels of three of these genes were again significantly altered by
fluoxetine treatment only in low-5HT, but not high-5HT, rats.
Specifically, 5HTT andHtr1amRNAs were downregulated, while
Htr4mRNA was upregulated by fluoxetine in low-5HT rats.
It is well-known that functional down-regulation of 5HTT
and 5HT1A autoreceptors by repeated SSRI administration is
important for the therapeutic effect. On the other hand, the
effects of repeated SSRI treatment on postsynaptic 5HT1A
receptors, which were also implicated in the therapeutic effect
(63) are inconclusive, showing either no changes in mRNA
levels (64, 65), or a reduction in mRNA with unchanged protein
levels (55, 58). The indicative decrease in Htr2a mRNA levels
in cortices from low-5HT animals suggest possible interaction
of measured synaptic proteins at a given post-treatment time
point. It has been suggested that fluoxetine-induced 5HT excess
simultaneously activates 5HT1A and 5HT2A receptors in the
pre-frontal cortex, leading to a balancing of inhibitory and
excitatory responses (66). Activation of postsynaptic 5HT4
receptors was proposed to mediate therapeutic response through
rapid desensitization of 5HT1A autoreceptors (62); SSRI-induced
increase in extracellular 5HT availability is shown to selectively
decrease 5HT4 receptor density in various 5HT projection areas
(67, 68). In the pre-frontal cortex, no changes in the density of
5HT4 binding sites were found after chronic fluoxetine treatment
(68), while here we observed increased mRNA expression in
fluoxetine-treated low-5HT, but not high-5HT animals.
The present work has shortcomings that must be mentioned.
First, behavioral tests were performed after 16 and 22 days of
treatment, while gene expression levels were measured after
27 fluoxetine injections. The different timing of the respective
measurements does not allow direct correlation of behavioral
and molecular data. Therefore, it is difficult to interpret the
results in high-5HT animals showing lack of molecular changes
in the brain in the presence of behavioral response, and vice
versa, the results in low-5HT animals showing lack of behavioral
response in the presence of molecular changes in the brain. It is
possible that the time course and/or capacity of adaptive changes
necessary to produce the behavioral or molecular effect show
different patterns in the 5HT-sublines. Next, the lack of protein-
level measurements of the genes of interest is another limitation
of our study. It is possible that measured mRNA levels may
not match corresponding protein levels at the given time points.
5HTT and 5HT1A receptors internalize in both cell bodies and
axon terminals after chronic fluoxetine treatment, so it is not
very uncommon for (functional) radioligand binding studies and
genetic expression studies to yield equivocal results (58, 69).
In conclusion, the present results show that higher
constitutional 5HT activity is associated with higher sensitivity
to anxiolytic effects of SSRI (fluoxetine) treatment. In addition to
highlighting the role of endogenous 5HT tone as an important
factor influencing behavioral response to antidepressants, our
results suggest that adaptive changes in cortical 5HTT, Htr1a,
and Htr4 expression levels in response to SSRI treatment are also
dependent on endogenous 5HT tone. Further studies are needed
to explain their interrelations with the behavioral response.
Finally, our results support plasma 5HT level as a predictor of
individual response to SSRI treatment, indicating its potential
utility as an early biomarker of therapeutic response in clinical
practice. In this regard, future research should include the
antidepressant effects of SSRI treatment in 5HT-sublines, with
low-5HT subline likely contributing to a better understanding
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of the neurobiology of treatment resistant anxiety/depression
in humans.
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12. Čičin-Šain L, Perović S, Iskrić S, Jernej B. Development of sublines of
Wistar-derived rats with high or low platelet serotonin levels. Period Biol.
(1995) 97:211–5.
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